1. Introduction {#sec1}
===============

Obesity results from energy imbalance. When energy intake chronically exceeds energy expenditure, white adipose tissue (WAT) dramatically expands to store the excess of energy as fat. Brown adipose tissue (BAT) is responsible for the maintenance of body core temperature leading to energy expenditure. This thermogenic function of BAT relies on the activity of uncoupling protein 1 (UCP1), which dissociates substrate oxidation from ATP production [@bib1]. In addition to its thermoregulatory function, UCP1 regulates whole-body energy homeostasis as its ablation leads to obesity in mice housed at thermoneutrality [@bib2]. Adult humans possess active BAT [@bib3], [@bib4], [@bib5]. BAT activity is negatively associated with adiposity, insulin resistance and aging. Therefore, therapeutics aimed at increasing BAT recruitment and activity appear conceivable strategies to fight obesity and its metabolic complications [@bib6].

Classical brown adipocytes are multilocular, UCP1-positive and thermogenically-competent cells residing in anatomically defined BAT depots. Following cold-exposure [@bib7], [@bib8], [@bib9] or treatments with β~3~-adrenergic receptor agonists [@bib10], [@bib11], [@bib12], brown-like fat cells are detected in mouse subcutaneous inguinal WAT depot [@bib13], [@bib14] where they are interspersed within unilocular UCP1-negative white adipocytes [@bib15]. In mice, browning of WAT is associated with protection against high-fat diet-induced obesity and insulin resistance [@bib16], [@bib17]. Brown-like adipocytes in WAT depots have been named brite (brown-in-white) or beige adipocytes. Two origins for brite adipocytes have been proposed. Brite fat cells may originate from *de novo* differentiation of precursor cells [@bib18], [@bib19] or arise from direct conversion of mature white fat cells [@bib7], [@bib20], [@bib21].

In humans, brite adipocytes have been observed in white fat depots [@bib22], [@bib23]. Morphological and histological data revealing cells with an intermediate phenotype suggest that conversion of white into brite adipocytes likely occurs [@bib22]. However, most studies investigating human brown/brite adipogenesis focused on differentiation of precursors into mature brown-like adipocytes [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]. Despite the therapeutic interest in the transformation of energy-storing into energy-dissipating adipocytes, data on fat and glucose metabolism during conversion from human white to brite fat cells are scarce. Notably, it is not established whether britening of white fat cells promotes both fatty acid and glucose utilization and how these changes are related to other metabolic pathways. Treatment with rosiglitazone, a PPARγ-specific agonist, of human multipotent adipose-derived stem (hMADS) cells previously differentiated into white adipocytes drives gene expression of brown/brite fat markers through the formation of PPARγ superenhancers [@bib29], [@bib30], [@bib31]. Long-term exposure to PPARα agonist induces a thermogenic programme in murine subcutaneous WAT [@bib32], [@bib33]. Furthermore, the two nuclear receptors are known positive regulators of UCP1 expression in mouse brown adipocytes [@bib34], [@bib35].

In the present work, conversion of white hMADS adipocytes into brite fat cells was induced with selective PPARγ and PPARα agonists to investigate fat and glucose metabolism. *In vivo*, subcutaneous WAT of wild type and PPARα-null mice were analyzed following chronic β~3~-adrenergic treatment.

2. Materials and methods {#sec2}
========================

2.1. hMADS adipocytes {#sec2.1}
---------------------

hMADS cells, established from the prepubic fat pad of a 4-month-old male (hMADS-3), were used between passages 16 and 25. hMADS cells were cultured and differentiated into white adipocytes as previously described [@bib36]. At day 14, 100 nM of the PPARγ agonist, rosiglitazone (Rosi), or 300 nM of the PPARα agonist, GW7647 (GW), were added to the differentiation medium for 4 additional days ([Figure S1A](#appsec2){ref-type="sec"}). Agonists were selected for being specific of each human PPAR subtype [@bib37], [@bib38]. Human fibroblast growth factor 2, insulin, triiodothyronine, transferrin, 3-isobutyl-1-methylxanthine, GW and dexamethasone were from Sigma; [l]{.smallcaps}-glutamine, penicillin, and streptomycin from Invitrogen; Hepes, low glucose Dulbecco\'s modified Eagle medium and Ham\'s F-12 medium from Lonza; Rosi from Alexis Biochemicals.

### 2.1.1. Triglyceride content {#sec2.1.1}

Lipid accumulation was visualized by Oil Red O staining of 10% formalin-fixed differentiated cells. Colorimetric quantitation of triglyceride content was performed using the triglyceride reagent commercial kit (Sigma). Values were normalized to protein concentration in cell lysates.

### 2.1.2. mRNA expression in hMADS cells {#sec2.1.2}

hMADS cells were harvested in RLT-β-mercaptoethanol 1% from the RNA extraction kit (Qiagen). Total RNA was extracted using RNeasy mini kit (Qiagen) and quantified by Nanodrop spectrophotometer (ThermoFischer Scientific). RNA (500 ng--1 μg) was reverse transcribed with the High capacity cDNA reverse transcription kit (Applied Biosystems) and qPCR was performed on a StepOnePlus thermocycler (ThermoFischer Scientific) using Fast SYBR green or Taqman fast advanced master mixes (Life Technologies). SYBR Green primers (Eurogentec) and Taqman probes (Life Technologies) are listed in [Tables S1 and S2](#appsec2){ref-type="sec"}. LRP10 was used as housekeeping gene.

### 2.1.3. DNA microarray {#sec2.1.3}

Total RNA from control and Rosi- or GW-treated cells (n = 4 for each condition) was extracted using a TRI-Reagent kit (Euromedex). RNA quality was checked by capillary electrophoresis (Experion, Bio-Rad). Microarray experiments were performed using Agilent 4 × 44k v2 oligonucleotide arrays as previously described [@bib39]. Microarray data have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number [GSE71293](ncbi-geo:GSE71293){#intref0010}. Significant microarray analysis (SAM) was performed to determine differentially expressed genes in Rosi- or GW-treated cells compared to control cells at day 18. Biological pathways and processes were analyzed using DAVID database v6.7 with Benjamini correction of p values [@bib40].

### 2.1.4. Western blot {#sec2.1.4}

Cells were lysed in RIPA buffer (Sigma) containing cocktail of protease and phosphatase inhibitors (Sigma). Equal amounts of solubilized proteins were loaded on 4--20% gradient SDS-PAGE gels (Bio-Rad), blotted onto nitrocellulose membranes and incubated with the following primary antibodies: HSL (\#4107), ATGL (\#2138) and GAPDH (\#2118) were purchased from CST Ozyme; total PDHE1α (\#Ab110334), phospho-Ser293 PDHE1α (\#Ab177461), UCP1 (\#Ab10983) and GLUT1 (\#Ab40084) from Abcam; PLIN5 (\#GP31) and PLIN 1 (\#GP29) from PROGEN; PDK4 (\#H00005166-A02) from Abnova and PCK1 (\#AP8093b) from Abgent. Anti-rabbit or anti-mouse IgG coupled to horseradish peroxidase were used as secondary antibodies. Immunoreactive proteins were determined by chemiluminescence (Clarity, Bio-Rad) with a ChemiDoc MP System (Bio-Rad) and quantification was performed using Image Lab software (Bio-Rad).

### 2.1.5. Substrate oxidation {#sec2.1.5}

Oleic acid oxidation and incorporation into triglycerides were assessed as described in Ref. [@bib41]. To determine pyruvate oxidation, insulin was removed from culture medium the day before assay. Cells were incubated for 3 h in 1 ml Krebs--Ringer Buffer (125 mM NaCl, 5 mM KCl, 2 mM CaCl~2~, 1.25 mM KH~2~PO~4~, 1.25 mM MgSO~4~, 25 mM NaHCO~3~) supplemented with 2% BSA, 10 mM HEPES, 2 mM glucose, 1 mM pyruvate and 0.5 μCi \[1-^14^C\]-pyruvic acid (PerkinElmer) with or without 100 nM insulin. Medium was then acidified with 1 M sulfuric acid in closed vials containing a central well filled with benzethonium hydroxide. After 3 h incubation, trapped ^14^CO~2~ was measured by liquid scintillation counting. Specific activity was measured and used to determine the quantity of oxidized pyruvate equivalent. Cells were washed with PBS and scraped in STED buffer (0.25 M sucrose, 10 mM Tris--HCl,1 mM EDTA, 1 mM dithiothreitol, pH 7.4). Results were normalized to protein content determined with Bio-Rad protein assay using BSA as standard.

### 2.1.6. Oxygen consumption {#sec2.1.6}

hMADS cells were seeded in 24 multi-well plates (Seahorse Bioscience) and differentiated as described above. Oxygen consumption rates (OCR) of 18 day-differentiated cells were determined using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). Basal OCR was calculated by subtraction of rotenone- and antimycin A-induced OCR (1 μM of each inhibitor) to the unstimulated OCR value. Analyses were also carried out in the presence of 50 μM etomoxir, a carnitine palmitoyltransferase 1 (CPT1) inhibitor. Maximal respiration was determined using FCCP (1 μM). Oleate- and pyruvate-driven OCR were measured after addition of 200 μM oleate and 5 mM pyruvate, respectively.

### 2.1.7. Lipolysis and re-esterification flux {#sec2.1.7}

Lipolysis was carried out as previously described [@bib42]. Briefly, after an overnight loading period, lipolysis of \[9,10-^3^H\]-oleic acid (PerkinElmer) was initiated by 1 μM of β-adrenergic receptor agonist isoproterenol with or without 10 μM triacsin C, an acyl-CoA synthetase inhibitor, to avoid fatty acid re-esterification. \[9,10-^3^H\]-oleic acid and glycerol released in the medium were measured respectively by liquid scintillation counting and commercially available kit (Sigma). The results were normalized to total protein content of cell extracts.

Glyceroneogenesis was measured by the incorporation of \[1-^14^C\]-pyruvic acid (PerkinElmer) into glycerol. Neutral lipids were extracted after pyruvic acid oxidation by adding 5 volumes chloroform:methanol (2:1) on cell lysate. After centrifugation, the organic phase was dried and hydrolyzed in 1 ml 0.25 N NaOH in chloroform:methanol (1:1) for 1 h at 37 °C. The solution was neutralized with 500 μl 0.5 N HCl in methanol. Fatty acids and glycerol were separated by adding 1.7 ml chloroform, 860 μl water and 1 ml chloroform:methanol (2:1). Incorporation of ^14^C-carbon into glycerol was measured in the upper phase by liquid scintillation counting.

Glycerol kinase activity was assessed by the incorporation of \[U-^14^C\]-glycerol (PerkinElmer) into triglycerides. Briefly, hMADS cells were incubated for 3 h in differentiation medium without glucose and pyruvate to avoid glyceroneogenesis. Then, fresh glucose/pyruvate-free differentiation medium supplemented with 0.3% BSA, 100 μM glycerol and 1 μCi \[U-^14^C\]-glycerol was added. After 2 h, the cells were washed with PBS and scraped with STED buffer for protein normalization. Neutral lipids were extracted and separated by thin layer chromatography to measure glycerol incorporation into triglycerides.

### 2.1.8. Pyruvate concentration {#sec2.1.8}

The day before the assay, insulin was removed from the culture medium. Cells were washed with PBS and incubated in glucose/pyruvate-free differentiation medium supplemented with 7.8 mM glucose. After 3 h, pyruvate released in the medium was measured using commercially available kit (BioAssay Systems). Cells were scraped in RIPA buffer for protein normalization.

### 2.1.9. Glucose uptake and *de novo* lipogenesis {#sec2.1.9}

Glucose uptake was measured using \[1,2-^3^H\]-2-deoxy-[d]{.smallcaps}-glucose as previously described [@bib43]. *De novo* lipogenesis was determined by \[1-^14^C\]-acetic acid incorporation into triglycerides. The day before the assay, insulin was removed from the culture medium. Cells were incubated for 3 h in Krebs--Ringer buffer (*cf.* Section [2.1.5](#sec2.1.5){ref-type="sec"}) supplemented with 2% BSA, 10 mM HEPES, 2 mM glucose, 5 mM acetate and 2 μCi \[1-^14^C\]-acetic acid (PerkinElmer), in the presence or absence of 100 nM insulin. Cells were scraped in STED buffer and neutral lipids were separated by thin layer chromatography.

### 2.1.10. RNA interference {#sec2.1.10}

mRNA knockdown was achieved using small interfering RNA (siRNA). Briefly, on day 7 of differentiation, hMADS cells were detached from culture dishes with trypsin/EDTA (Invitrogen) and counted. One hundred picomol of a pool of either 4 siRNAs targeting PDK4 or 4 non-targeted control siRNAs (ThermoFischer Scientific) were delivered into adipocytes by a microporator (Invitrogen), with the following parameters: 1,100 V, 20 ms, 1 pulse. The targeted sequences were: siControl pool 1: 5′-UGGUUUACAUGUCGACUAA-3′; siControl pool 2: 5′-UGGUUUACAUGUUGUGUGA-3′; siControl pool 3: 5′-UGGUUUACAUGUUUUCUGA-3′; siControl pool 4, 5′-UGGUUUACAUGUUUUCCUA-3′; siPDK4 pool 1: 5′-GACCGCCUCUUUAGUUAUA-3′; siPDK4 pool 2: 5′-CAACGCCUGUGAUGGAUAA-3′; siPDK4 pool 3: 5′-CGACAAGAAUUGCCUGUGA-3′; siPDK4 pool 4: 5′-GAGCAUUUCUCGCGCUACA-3′.

2.2. Human primary adipocytes {#sec2.2}
-----------------------------

Human subcutaneous abdominal adipose tissue was collected from abdominoplasty of healthy patients for stromavascular fraction isolation according to the procedure previously described [@bib29]. Stromavascular fraction cells were plated and maintained in DMEM containing 10% FCS until confluence. Differentiation of primary cultures was performed according to the protocol described for hMADS cells.

2.3. *In vivo* mouse studies {#sec2.3}
----------------------------

Mouse studies were performed in accordance with French and European animal care facility guidelines. A first cohort of 21 week-old PPARα-null male mice on C57BL/6J genetic background and their wild-type (WT) counterparts were acclimated at thermoneutral temperature (30 ± 1 °C) for 4 weeks, on a 12/12 h light/dark cycle with *ad libitum* water and food. Mice were treated for 10 days with the β~3~-adrenergic receptor agonist CL316,243 (0.1 mg/kg/d) (Sigma) or vehicle (DMSO) by daily intraperitoneal injections. A second cohort of 10 week-old mice was housed at standard room temperature (21 ± 1 °C). Mice were treated for 7 days with CL316,243 (1 mg/kg) or vehicle by daily intraperitoneal injections. After an overnight fast, mice were killed by cervical dislocation, and tissues were rapidly sampled and frozen in liquid nitrogen before being stored at −80 °C.

### 2.3.1. mRNA expression {#sec2.3.1}

Inguinal WAT or interscapular BAT samples were homogenized in Qiazol buffer (Qiagen) using Precellys homogenizer (Ozyme). Total RNA samples were processed as described in Section [2.1.2](#sec2.1.2){ref-type="sec"}. SYBR Green primers (Eurogentec) and Taqman probes (Life Technologies) are listed in [Tables S1 and S2](#appsec2){ref-type="sec"}.

### 2.3.2. Western blot {#sec2.3.2}

Tissues were powdered in liquid nitrogen and homogenized in RIPA buffer (Sigma) containing cocktail of protease and phosphatase inhibitors (Sigma). Western blotting was then performed as described in Section [2.1.4](#sec2.1.4){ref-type="sec"}. Proteins of interest were normalized to total blotted proteins by using stain-free gels (Bio-Rad).

2.4. Statistical analyses {#sec2.4}
-------------------------

Statistical analyses were performed using GraphPad Prism (GraphPad Software v.5.0). Paired or unpaired one-way ANOVA were performed and followed by Tukey\'s *post hoc* test to determine differences between groups. Two-way ANOVA, followed by Bonferroni\'s *post hoc* test, was applied when appropriate. Data are presented as percent of control cells or percent of WT untreated-mice, ±SEM, unless otherwise described in legend. Statistical significance was set at p \< 0.05.

3. Results {#sec3}
==========

3.1. PPARγ and PPARα agonists promote britening of human white adipocytes {#sec3.1}
-------------------------------------------------------------------------

Treatments with PPARγ (Rosi) or PPARα (GW) agonists added for 4 days on differentiated white adipocytes ([Figure S1A](#appsec2){ref-type="sec"}) increased UCP1 mRNA and protein levels (15- and 11-fold increase, respectively) ([Figure 1](#fig1){ref-type="fig"}A,B), as well as expression of genes classically elevated in brown and brite fat cells (*CIDEA*, *CPT1b*, *ELOVL3*, *PGC1α*) ([Figure 1](#fig1){ref-type="fig"}A). We next determined whether PPAR agonist-treated adipocytes expressed brown- and brite-specific markers. Brown markers were not (*MPZL* and *LHX8*) expressed or were weakly (*ZIC1*) expressed and not regulated by treatments ([Figure 1](#fig1){ref-type="fig"}C and data not shown). By contrast, expression of brite adipocyte markers *TMEM26*, *TBX1* and *CITED1* was increased ([Figure 1](#fig1){ref-type="fig"}D). Altogether, these data indicate that upon PPARγ or PPARα activation, hMADS white adipocytes display a molecular pattern of brite fat cells.

Gene expression levels of the white adipocyte markers *TCF21*, *DPT*, *LEP*, *HOXC9* and *PLIN1* were barely, or not at all, regulated by PPAR agonists ([Figure 1](#fig1){ref-type="fig"}E). Accordingly, protein level of PLIN1 was not modified by treatments ([Figure 1](#fig1){ref-type="fig"}F). Triglyceride content of differentiated adipocytes was not altered ([Figure 1](#fig1){ref-type="fig"}G). The two PPAR agonists induced down-regulation of *PPARγ* mRNA level with no effect on other members of the *PPAR* family ([Figure S1B](#appsec2){ref-type="sec"}).

The results were confirmed in primary human differentiated preadipocytes. In Rosi- and GW-treated primary adipocytes, mRNA expression of *UCP1* and of several other thermogenic genes was upregulated ([Figure 1](#fig1){ref-type="fig"}H), while white and adipogenic markers were not changed ([Figure S1C](#appsec2){ref-type="sec"}). mRNA levels of the brite markers *TBX1* and *CITED1* increased as observed in treated hMADS cells ([Figure S1D](#appsec2){ref-type="sec"}).

3.2. PPARγ and PPARα agonists drive similar transcriptional response and mitochondrial adaptation in white adipocytes {#sec3.2}
---------------------------------------------------------------------------------------------------------------------

DNA microarrays were used to investigate the whole transcriptional effects of PPARγ and PPARα agonists on hMADS cells. SAM analysis of 12891 transcripts using false discovery rate of 5% revealed that, compared to untreated white adipocytes, 265 and 210 genes were significantly up- and down-regulated by Rosi, respectively, and 470 and 209 genes were significantly up- and down-regulated by GW, respectively (data not shown).

Among the 215 genes upregulated by the two treatments, 96 and 57 were induced by more than 3-fold by Rosi and GW, respectively. On the contrary, genes upregulated specifically by Rosi or GW displayed weak fold induction, suggesting major overlap in the regulation of gene expression by PPARγ and PPARα agonists in adipocytes. Consistent with these findings, several lipid metabolism-related biological processes were found to be regulated by both Rosi and GW ([Table 1](#tbl1){ref-type="table"}). RT-qPCR confirmed that expression of genes involved in fatty acid uptake, activation and esterification was increased in brite fat cells ([Figure S2A](#appsec2){ref-type="sec"}). Gene ontology analysis also revealed that both fatty acid anabolism and catabolism were activated during britening ([Table 1](#tbl1){ref-type="table"} and [Table S3](#appsec2){ref-type="sec"}) as confirmed by RT-qPCR data of major genes driving triglyceride synthesis and fatty acid oxidation ([Figure 1](#fig1){ref-type="fig"}A and [Figure S2B,C](#appsec2){ref-type="sec"}). A few genes showed down-regulated expression. Fold changes were markedly lower than upregulated genes: only 14 out of 210 and 4 out of 209 genes were decreased by more than 3-fold by Rosi and GW, respectively.

Collectively, these results show that the two agonists have a profound effect on fatty acid anabolic and catabolic pathways.

Besides fatty acid metabolism, DNA microarrays showed upregulation of a number of mitochondrial genes by Rosi and GW. RT-qPCR measurements confirmed the upregulation of several subunits of the mitochondrial electron transport chain ([Figure S2D](#appsec2){ref-type="sec"}). This was associated with slightly higher mitochondrial biogenesis assessed by mitochondrial DNA content ([Figure S2E](#appsec2){ref-type="sec"}) and a sharp increase in maximal oxygen consumption in brite adipocytes ([Figure S2F](#appsec2){ref-type="sec"}). Given the weak induction of mitochondrial biogenesis compared to the boosted mitochondrial respiration, our results suggest major metabolic adaptations associated with britening.

3.3. Britening of white adipocytes induces anabolic and catabolic pathways of fat metabolism {#sec3.3}
--------------------------------------------------------------------------------------------

Britening of hMADS adipocytes was associated with increased oleate incorporation into triglycerides as suggested by gene upregulation ([Figure 2](#fig2){ref-type="fig"}A, [Figure S2A](#appsec2){ref-type="sec"} and [Table S3](#appsec2){ref-type="sec"}). Newly activated fatty acids require glycerol-3-phosphate as a backbone for esterification. Glycerol kinase, an enzyme with higher expression in BAT than in WAT, showed strong induction in response to the treatments ([Figure 2](#fig2){ref-type="fig"}B). Accordingly, glycerol incorporation into triglycerides was enhanced ([Figure 2](#fig2){ref-type="fig"}C).

Increased fat synthesis was associated with enhanced triglyceride breakdown. The lipolytic capacity assessed by glycerol release into the medium in response to isoproterenol, a pan β-adrenergic receptor agonist, was enhanced ([Figure 2](#fig2){ref-type="fig"}D), along with increase of mRNA and protein expression of the two main lipases: ATGL and HSL ([Figure 2](#fig2){ref-type="fig"}E and [Figure S3A](#appsec2){ref-type="sec"}). Gene expression of AQP7, a transporter facilitating glycerol efflux, was also upregulated ([Figure S3B](#appsec2){ref-type="sec"}).

In line with the induction of numerous genes involved in fatty acid mitochondrial transport and oxidation ([Table S3](#appsec2){ref-type="sec"}), britening sharply increased oleate oxidation ([Figure 2](#fig2){ref-type="fig"}F). mRNA and protein levels of PLIN5, a lipid droplet binding protein involved in fatty acid oxidation, were strongly enhanced ([Figure 2](#fig2){ref-type="fig"}G and [Figure S2C](#appsec2){ref-type="sec"}). Oxygen consumption in brite adipocytes was higher than in white fat cells ([Figure 2](#fig2){ref-type="fig"}H). After addition of etomoxir, a carnitine palmitoyltransferase 1 inhibitor, the oxygen consumption of brite adipocytes was blunted to the level of white adipocytes ([Figure 2](#fig2){ref-type="fig"}H), indicating that, in contrast to white fat cells, the higher metabolic rate of brite fat cells is linked to fatty acid oxidation. In agreement with these results, oleate addition increased OCR only in brite adipocytes ([Figure 2](#fig2){ref-type="fig"}I), further demonstrating the elevated capacity of brite fat cells to oxidize fatty acids.

Taken together, these data show that britening of white adipocytes is associated with major adaptations in fatty acid metabolism, promoting both triglyceride synthesis and hydrolysis and driving fatty acid fluxes towards mitochondrial oxidation.

3.4. Britening of white adipocytes promotes a shift of glucose metabolism from oxidation towards glycerol production {#sec3.4}
--------------------------------------------------------------------------------------------------------------------

Basal and insulin-stimulated glucose uptakes were decreased in brite adipocytes ([Figure 3](#fig3){ref-type="fig"}A). This was consistent with decreased mRNA and protein levels of the glucose transporter GLUT1 ([Figure 3](#fig3){ref-type="fig"}B). *GLUT1* expression was strongly correlated with basal glucose transport ([Figure S4A](#appsec2){ref-type="sec"}). Insulin sensitivity evaluated by the insulin stimulated-to-basal glucose uptake ratio was preserved ([Figure 3](#fig3){ref-type="fig"}C) as was gene expression level of the insulin-responsive glucose transporter *GLUT4* ([Figure 3](#fig3){ref-type="fig"}B).

To directly assess glucose oxidation without the confounding effect of changes in glucose uptake and glycolysis, we used radiolabelled pyruvate, the end-product of glycolysis. Pyruvate uptake was not modified by the treatments ([Figure 3](#fig3){ref-type="fig"}D). Britening decreased pyruvate oxidation by up to 50% in basal and insulin-stimulated conditions ([Figure 3](#fig3){ref-type="fig"}E). Pyruvate flux was redirected towards other pathways in brite adipocytes as shown by higher pyruvate release into the medium ([Figure 3](#fig3){ref-type="fig"}F) and by activation of glyceroneogenesis leading to increased incorporation of pyruvate into the glycerol backbone of neutral lipids ([Figure 3](#fig3){ref-type="fig"}G). This glycerol-3-phosphate synthesis pathway is highly dependent on phosphoenolpyruvate carboxykinase 1 (PCK1) activity, which mRNA and protein levels were sharply increased in response to Rosi and GW ([Figure 3](#fig3){ref-type="fig"}H). Glycerol-3-phosphate dehydrogenase 1 gene expression was also upregulated in brite adipocytes ([Figure S4B](#appsec2){ref-type="sec"}). The newly formed glycerol-3-phosphate allowed fatty acid re-esterification, which is demonstrated by the moderate release of fatty acids compared to glycerol following β-adrenergic receptor agonist stimulation ([Figure 2](#fig2){ref-type="fig"}, [Figure 3](#fig3){ref-type="fig"}). To directly assess glucose carbon incorporation into fatty acids *i.e., de novo* lipogenesis, radiolabelled acetate was used. The change in brite adipocytes was marginal as was the changes in cognate gene expression ([Figure S4C,D](#appsec2){ref-type="sec"}).

These results point at intracellular pyruvate as a central node in brite adipocyte glucose metabolism. One of the top-ranking genes upregulated by the two treatments in the DNA microarray analyses and confirmed by RT-qPCR ([Figure 3](#fig3){ref-type="fig"}J) was pyruvate dehydrogenase kinase 4 (*PDK4*), which phosphorylates the pyruvate dehydrogenase complex (PDH). PDK4 protein level was strongly upregulated, leading to higher PDH phosphorylation on the E1α subunit in brite adipocytes ([Figure 3](#fig3){ref-type="fig"}K). *PDK1*, *2* and *3* were more modestly upregulated during britening ([Figure 3](#fig3){ref-type="fig"}J). In human primary adipocytes, PPAR agonists also upregulated *PDK4* gene expression ([Figure S4E](#appsec2){ref-type="sec"}).

Altogether, our observations show that, in human brite adipocytes, glucose metabolism switches from oxidation towards glycerol-3-phosphate production, favoring triglyceride synthesis. Moreover, the strong induction of PDK4, through phosphorylation of the PDH complex, invokes a shift in fuel selection favoring oxidation of fatty acids instead of glucose.

3.5. PDK4 knockdown prevents induction of fatty acid oxidation in brite adipocytes {#sec3.5}
----------------------------------------------------------------------------------

To directly address the role of PDK4 in the metabolic remodeling associated with britening of hMADS cells, siRNA-mediated knockdown was validated at mRNA and protein levels ([Figure 4](#fig4){ref-type="fig"}A). There was no alteration in the expression of *UCP1*, brown and brite markers and of other *PDK* isoforms ([Figure 4](#fig4){ref-type="fig"}B and [Figure S5A,B](#appsec2){ref-type="sec"}). Decreased PDK4 expression resulted in lower PDH phosphorylation ([Figure 4](#fig4){ref-type="fig"}C). Consequently, pyruvate release from brite adipocytes was decreased to the levels observed in white adipocytes ([Figure 4](#fig4){ref-type="fig"}D) and britening-induced glyceroneogenesis was partially inhibited ([Figure 4](#fig4){ref-type="fig"}E). Concomitantly, PDK4 knockdown restored pyruvate oxidation in brite fat cells ([Figure 4](#fig4){ref-type="fig"}F). Consistent with higher pyruvate oxidation, pyruvate-driven OCR raised by up to 50% over basal in white and PDK4 siRNA-treated brite adipocytes while brite adipocytes did not respond to pyruvate addition ([Figure S5C](#appsec2){ref-type="sec"}). Contrary to pyruvate oxidation, PDK4 siRNA treatment blunted fatty oxidation in brite adipocytes ([Figure 4](#fig4){ref-type="fig"}G). Basal OCR in brite adipocytes, which is highly dependent on fatty acid oxidation ([Figure 2](#fig2){ref-type="fig"}H,I), returned to white fat cell level upon PDK4 knockdown ([Figure S5D](#appsec2){ref-type="sec"}), similarly to what was observed when fatty acid oxidation was prevented by etomoxir ([Figure 2](#fig2){ref-type="fig"}H). However, fatty acid oxidation remained higher in PDK4 siRNA-treated brite compared to white adipocytes ([Figure 4](#fig4){ref-type="fig"}G), suggesting that other mechanisms such as increased expression of fatty acid metabolism genes ([Figure S5A](#appsec2){ref-type="sec"} and [Table S3](#appsec2){ref-type="sec"}) were involved. Fatty acid esterification was not altered by PDK4 knockdown ([Figure S5E](#appsec2){ref-type="sec"}), demonstrating that PDK4 specifically regulates the oxidative metabolism of fatty acids.

Collectively, these results suggest that PDK4 has a major role, independently of the britening process *per se*, in regulating the preference for fatty acids over glucose for mitochondrial oxidation of brite fat cells.

3.6. PPARα deficiency disrupts WAT britening-induced PDK4 expression *in vivo* {#sec3.6}
------------------------------------------------------------------------------

Data in human adipocytes indicated that PDK4 induction was responsible for major metabolic adaptations during britening. To confirm these *in vitro* results, we aimed at investigating PDK4 regulation *in vivo*. As PPARγ but not PPARα deficiency in WAT provokes lipodystrophy, PPARα-null mice were used. Inguinal WAT was investigated as it is a fat depot prone to britening compared to other fat pads.

Two cohorts of mice were investigated. WT and PPARα-null mice at 21 weeks of age acclimated at thermoneutrality were treated with the β~3~-adrenergic agonist CL316,243. Acclimation to thermoneutrality is essential to avoid the confounding effects due to activation of brown and brite fat depots at conventional housing temperature. Body weight and inguinal fat pad weight were higher in PPARα-null mice compared to age-matched WT mice ([Figure S6A](#appsec2){ref-type="sec"}). As the difference in adiposity between genotypes may influence britening in inguinal fat pad and obesity in PPARα-null mice develops with aging [@bib44], CL treatment was applied to younger mice housed at standard temperature. As expected, there was no difference in body and inguinal fat pad weights between 11 week-old WT and PPARα-null mice ([Figure S6B](#appsec2){ref-type="sec"}). *Pparα* mRNA was, respectively, undetectable and expressed at low level in inguinal WAT of vehicle-treated PPARα-null and WT mice and was induced upon chronic β~3~-adrenergic stimulation only in WT mice ([Figure S6C,D](#appsec2){ref-type="sec"}). UCP1 mRNA and protein were barely detectable in WAT of vehicle-treated WT and PPARα-null mice. Upon CL316,243 treatment, UCP1 expression in WAT was sharply induced in WT mice while this increase was markedly blunted in PPARα-null mice ([Figure 5](#fig5){ref-type="fig"}A,B). PPARα deficiency did not impair white adipogenesis as shown by similar expression of *Pparγ* and *Dpt*, a white adipocyte specific marker [@bib35], in both WT and PPARα-null mice ([Figure S6E](#appsec2){ref-type="sec"}). Inguinal WAT mRNA levels of the classical markers of thermogenic cells, *Cidea* and *Cpt1b*, were barely detectable in vehicle-treated mice and sharply increased upon β~3~-adrenergic agonist treatment in WT mice, while this induction was impaired in PPARα-null mice as thermogenic genes ([Figure 5](#fig5){ref-type="fig"}C,D). Classical brite adipocyte markers such as *Cited1* and *Tmem26* displayed the same pattern ([Figure 5](#fig5){ref-type="fig"}E,F). Noteworthy, the expression of these genes was induced by CL316,243 in interscapular BAT of both WT and PPARα-null mice ([Figure S6F](#appsec2){ref-type="sec"}), suggesting a specific role of PPARα in brite fat cells compared to brown fat cells upon chronic β~3~-adrenergic stimulation. PDK4 expression was upregulated in inguinal WAT at mRNA and protein levels during CL316,243 treatment in WT mice, while this induction was severely blunted in PPARα-null mice ([Figure 5](#fig5){ref-type="fig"}G,H). Supporting the induction of PDK4 as a major feature of britening, PDK4 expression was strongly correlated with UCP1 expression at both protein and mRNA levels in inguinal WAT ([Figure 5](#fig5){ref-type="fig"}I and [Figure S6G](#appsec2){ref-type="sec"}).

4. Discussion {#sec4}
=============

Understanding the role of brown and brite adipocytes in humans may result in strategies aimed at dissipating the energy surplus and improving metabolism in obesity and related disorders. Little is known about the metabolic adaptations during white-to-brite adipocyte conversion. Herein, we investigated the molecular and metabolic changes following chronic PPARγ or PPARα activation of human mature white adipocytes. Our results robustly show that PPAR agonists are able to promote white-to-brite conversion as shown by a sharp induction of UCP1 as well as numerous thermogenic genes and brite adipocyte markers. DNA microarray experiments reveal that these agonists drive profound changes in energy metabolism. Britening promotes higher mitochondrial oxygen consumption which is associated with enhanced fatty acid anabolism and catabolism whereas glucose oxidation is diminished. Instead, glucose utilization is redirected towards glyceroneogenesis and favors triglyceride synthesis. The shift from glucose to fatty acid as preferential energy substrate is partly mediated by the metabolic switch PDK4. *In vivo*, PPARα-null mice display altered UCP1 and PDK4 induction in inguinal WAT in response to β~3~-adrenergic agonist-induced britening.

The brown identity of a fat cell relies on its capacity to sustain thermogenesis *i.e.,* to possess high mitochondrial oxidative capacities associated with activation of the *bona fide* uncoupling protein, UCP1. Here, we report that human mature white adipocytes can acquire these brown fat cell properties upon PPARγ or PPARα activation. In addition to the upregulation of genes that characterize both brown and brite adipocytes compared to white fat cells, other markers have been identified in mouse studies to distinguish the brite from the brown cell type. Defining the molecular signature of human UCP1-positive adipocytes using murine brite-specific genes led to conflicting results reporting either classical brown [@bib45], [@bib46], [@bib47] or brite [@bib19], [@bib27], [@bib48] profiles, which may depend on the depth in the adipose depot considered [@bib49]. These data were inferred from gene expression measurements in fat biopsies or in precursor cells differentiated *in vitro* in either white or brown/brite adipocytes. The profile of human mature white adipocytes converted into brown/brite cells has not been explored so far although this mechanism contributes *in vivo* to a great extent to the appearance of brite adipocytes in the mouse inguinal WAT depot [@bib20], [@bib21]. Here, we provide evidence that human mature white adipocytes are capable of switching towards a brite phenotype since higher expression of brite markers is observed while classical brown genes are not regulated or poorly expressed.

PPARγ and PPARα have well established roles in driving adipogenesis/triglyceride storage and fatty acid oxidation, respectively, in fat cells [@bib50]. PPARγ role in brown fat cell differentiation has been extensively studied. The contribution of PPARα, besides the regulation of fat utilization genes, is more elusive. Our data suggest that, in human white fat cells, PPARγ and PPARα agonists have the same britening efficiency, as demonstrated by the wide overlap of regulated genes and by the absence of noticeable difference between the two treatments in any of the parameters investigated. The requirement of PPARα for WAT britening is confirmed in PPARα-null mice which display a disrupted induction of thermogenic and brite markers in the inguinal fat depot upon β~3~-adrenergic agonist treatment. Our results support the findings that direct [@bib32], [@bib33] or indirect [@bib51], [@bib52] PPARα activation in murine WAT and cultured white adipocytes promotes britening. Contrasting with WAT, we show that BAT response to CL316,243 treatment is similar in WT and PPARα-null mice, which stresses that PPARα is dispensable for activation of BAT as previously suggested [@bib53]. These mechanistic differences between WAT britening and BAT activation further highlight the need for suitable human cell models of white-to-brite conversion such as hMADS cells [@bib54].

Classical detection of BAT activity *in vivo* relies on its capacity to take up high amounts of glucose in response to sympathetic stimulation. Unexpectedly, our data report a slight but significant lower basal glucose uptake in human brite adipocytes associated with a down-regulation of GLUT1 mRNA and protein levels. *GLUT1* expression and basal glucose transport are highly correlated, further supporting the importance of GLUT1 in basal glucose uptake of hMADS adipocytes. In response to insulin, the magnitude of glucose uptake increase is the same in white and brite adipocytes, showing that insulin sensitivity is preserved. Differentiation of WAT precursor cells into brown-like fat cells has been associated with increased or decreased basal glucose uptake and GLUT1 expression, suggesting that browning and glucose uptake are not necessarily linked [@bib55], [@bib56].

Britening of human white adipocytes is associated with an inhibition of carbohydrate oxidation and an upregulation of PDK4. These findings are consistent with the recent report by Loft et al. revealing that knockdown of the transcription factor KLF11 in hMADS adipocytes simultaneously impairs PPARγ-mediated browning and PDK4 upregulation [@bib30]. Our *in vivo* data show that britening of WAT triggers sharp PDK4 mRNA and protein upregulation. Conversely, impaired britening in CL316,243-treated PPARα-null mice is associated with lower PDK4 induction. PDK4 activity inhibits glucose-derived substrate oxidation through phosphorylation-mediated inactivation of the PDH complex. Consequently, PDH activity is blunted [@bib57], making glucose available for energy substrate replenishment rather than for oxidation [@bib58], [@bib59]. Pyruvate is redirected towards glyceroneogenesis to provide glycerol-3-phosphate backbone for fatty acid esterification [@bib60]. Accordingly, glyceroneogenesis, the main glycerol-producing pathway in adipocytes [@bib61], and its essential enzyme PCK1 are strongly induced during britening of human adipocytes. Concurrently, other glycerol-3-phosphate-producing pathways are activated *i.e.,* glycerol-3-phosphate dehydrogenase and glycerol kinase pathways. Interestingly, while PPARα in liver controls glycerol uptake and conversion into glucose [@bib62], our results show that britening of white adipocytes is associated with activation of glucose-derived glycerol production and release. This suggests a PPARα-controlled *in vivo* metabolic crosstalk between adipose tissue and liver. PPARα may control the britening of white adipocytes leading to enhanced glycerol release, which in turn can be used by the liver as a neoglucogenic substrate, another PPARα-activated pathway. Additionally, we find that fatty acid esterification, lipolysis and fatty acid oxidation are simultaneously enhanced after britening both at the molecular and functional levels. The stimulation of both fatty acid esterification and degradation activates a futile triglyceride/fatty acid cycle contributing to intracellular fatty acid use and leading to a fine tuning of metabolic fluxes [@bib61], [@bib63], [@bib64]. This mechanism may prevent an excessive release of fatty acids from fat depots known to promote lipotoxicity and insulin resistance. Importantly, these combined metabolic adaptations occur in the absence of changes in triglyceride content, and thus may not aggravate obesity at the whole-organism level.

As glucose is spared to supply replenishing pathways with britening, fatty acids become the favorite substrate for mitochondrial oxidation. This is demonstrated by higher fatty acid oxidation in brite adipocytes, whose induction is inhibited when glucose availability for oxidation is restored after PDK4 knockdown. It is noteworthy that the higher basal oxygen consumption in brite adipocytes returns to control value when fatty acid oxidation is prevented by etomoxir, further supporting the affinity of brite cells for fatty acids as mitochondrial substrates. These results are in agreement with *in vivo* findings showing that mice treated with a β~3~-adrenergic agonist exhibit higher whole-body fatty acid oxidation and lower respiratory quotient, indicative of a metabolic switch towards fat oxidation [@bib65]. Furthermore, mice treated with niacin in order to block lipolysis show an altered thermogenic response, suggesting that fatty acids are the main energy source for thermogenesis in activated rodent BAT [@bib59]. Consistent with mice data, clinical studies report a rapid decrease of BAT triglyceride content in cold-exposed patients, further pointing to fatty acids as the major energy substrates supplying thermogenic cells [@bib66], [@bib67]. As it seems that cold-induced fatty acid oxidative metabolism in BAT is not impaired in type 2 diabetic patients [@bib68], increasing the thermogenic capacity by white-to-brite adipocyte conversion appears as a valuable strategy.

5. Conclusion {#sec5}
=============

Collectively, our results demonstrate for the first time that human mature white adipocytes can be converted into brite cells expressing thermogenic markers and displaying a wide metabolic reprogramming. We identified PDK4 as a crucial mediator redirecting glucose towards triglyceride synthesis, thereby favoring fatty acid use as energy substrate for uncoupling mitochondria. Human brite adipocytes are endowed with higher capacity for intra-adipose fatty acid oxidation and thus could be targeted to diminish fatty acid plasma level and their storage into ectopic insulin-sensitive tissues, in order to prevent obesity-associated insulin resistance and type 2 diabetes.
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The following are the supplementary data related to this article:

**Figure S1: PPARγ and PPARα agonists promote britening of human white adipocytes.** (**A**) hMADS cells were firstly differentiated into white adipocytes within 14 days, then treated or not (C) with rosiglitazone (R) or GW7647 (GW) for 4 additional days. (**B**) Gene expression levels of *PPAR* subtypes in hMADS adipocytes. (**C**) Gene expression levels of white-specific markers and (**D**) brite-specific markers in human primary adipocytes. Data represent mean ± SEM expressed as percentage of control (n = 6--12) for hMADS cells and (n = 2--4) for primary adipocytes. Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*\*\*: p \< 0.001 for R or GW *vs*. C.

**Figure S2: PPARγ and PPARα agonists drive similar transcriptional response and mitochondrial adaptation in white adipocytes.** (**A**) mRNA levels of genes involved in fatty acid transport and activation, (**B**) fatty acid esterification, (**C**) fatty acid oxidation and (**D**) electron transport chain subunits. (**E**) Mitochondrial DNA content. (**F**) Maximal mitochondrial oxygen consumption rates (OCR). Data represent mean ± SEM expressed as percentage of control (n = 6--12). Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \#\#\#: p \< 0.001 for R *vs*. GW.

**Figure S3: Britening of white adipocytes induces anabolic and catabolic pathways of fat metabolism.** (**A**) Gene expression levels of the lipases *ATGL* and *HSL* and (**B**) AQP7. Data represent mean ± SEM expressed as percentage of control (n = 13). Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*\*: p \< 0.01 for R or GW *vs*. C; \*\*\*: p \< 0.001.

**Figure S4: Britening of white adipocytes promotes a shift of glucose metabolism from oxidation towards glycerol production.** (**A**) Pearson correlation between *GLUT1* mRNA content and glucose uptake (n = 9). (**B**) Gene expression level of *GPD1*. (**C**) *De novo* lipogenesis assessed by acetate incorporation into neutral lipids. (**D**) mRNA levels of major genes involved in *de novo* lipogenesis. (**E**) PDK4 mRNA levels in human primary adipocytes. Data represent mean ± SEM expressed as percentage of control (n = 5--10) for hMADS cells and (n = 2--4) for primary adipocytes. Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$\$\$: p \< 0.001 for insulin *vs*. unstimulated condition. \#\#: p \< 0.01 for R *vs*. GW.

**Figure S5: PDK4 knockdown prevents induction of fatty acid oxidation in brite adipocytes.** (**A**) Gene expression levels of thermogenic (*CPT1b* and *ELOVL3*) and brite (*TMEM26*) markers and, (**B**) of the different *PDK* isoforms. (**C**) Mitochondrial oxygen consumption rates (OCR) measured after addition of 5 mM pyruvic acid and (**D**) basal OCR. (**E**) Fatty acid (oleate) incorporation into triglycerides (TG). Data represent mean ± SEM expressed as percentage of control (n = 5--8). (**A**, **B** and **E**) Open bars: siCtrl-treated cells, full bars: siPDK4-treated cells. (**C** and **D**) Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: rosiglitazone + siPDK4-treated cells (R + siPDK4) \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \#: p \< 0.05 for R + siPDK4 *vs*. R.

**Figure S6: PPARα deficiency disrupts WAT britening-induced PDK4 expression *in vivo*.** (**A**, **C**, **E**, **F** and **G**) WT and PPARα-null male mice housed at thermoneutrality were treated with CL316,243 (CL, 0.1 mg/kg/d) or vehicle (DMSO) for 10 days. (**B** and **D**) WT and PPARα-null male mice housed at standard temperature (21 °C) were treated with CL316,243 (CL, 1 mg/kg/d) or vehicle (DMSO) for 7 days. (**A** and **B**) Body weight and inguinal fat pad (iWAT) weight of WT and PPARα-null mice. (**C** and **D**) iWAT mRNA expression levels of *Pparα*, (**E**), *Pparγ* (white-specific marker) and *Dpt* (adipogenic marker). (**F**) Interscapular BAT gene expression levels of *Ucp1*, *Cidea*, *Cited1* and *Tmem26*. Data represent mean ± SEM expressed as percentage of vehicle-treated WT mice (n = 7--9 mice per group). Open bars: wild-type mice, hatched bars: PPARα-null mice. ND: not detectable. \*: p \< 0.05 for CL *vs*. DMSO; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$: p \< 0.05 for PPARα-null *vs*. wild type; \$\$: p \< 0.01; \$\$\$: p \< 0.001. (**F**) Spearman correlation between *Ucp1* and *Pdk4* mRNA level (n = 32).
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![**PPARγ and PPARα agonists promote britening of human white adipocytes.** (**A**) Gene expression levels of thermogenic genes. (**B**) UCP1 protein content. Gene expression levels of (**C**) brown-, (**D**) brite- and (**E**) white-specific markers. (**F**) PLIN1 protein content. (**G**) Pictures representative of Oil Red O staining in each condition at day 18. Intracellular triglyceride (TG) content quantified by enzymatic assay. (**H**) mRNA levels of thermogenic genes in human adipocytes differentiated in primary culture. Data represent mean ± SEM expressed as percentage of control (n = 6--12) for hMADS cells and (n = 2--4) for primary adipocytes. Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001.](gr1){#fig1}

![**Britening of white adipocytes induces anabolic and catabolic pathways of fat metabolism.** Fatty acid metabolism was investigated in 18 day-differentiated hMADS cells treated or not with rosiglitazone or GW7647 for the last 4 days. (**A**) Fatty acid (oleate) incorporation into triglycerides (TG). (**B**) Gene expression level of glycerol kinase (*GK*). (**C**) Glycerol incorporation into triglycerides. (**D**) Glycerol release after stimulation by the β-adrenergic agonist, isoproterenol. (**E**) ATGL and HSL protein content. (**F**) Fatty acid (oleate) oxidation. (**G**) PLIN5 protein content. (**H**) Basal mitochondrial oxygen consumption rates (OCR) in the presence or not of 50 μM etomoxir. (**I**) OCR measured after addition of 200 μM oleate. Data represent mean ± SEM expressed as percentage of control (n = 7--12). Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$\$\$: p \< 0.001 for etomoxir *vs*. basal condition.](gr2){#fig2}

![**Britening of white adipocytes promotes a shift of glucose metabolism from oxidation towards glycerol production.** Glucose metabolism was investigated in 18 day-differentiated hMADS cells treated or not with rosiglitazone or GW7647 for the last 4 days. (**A**) Glucose transport in the presence or not of 100 nM insulin. (**B**) Gene expression levels of the glucose transporters *GLUT1* and *GLUT4* and GLUT1 protein level. (**C**) Insulin sensitivity estimated by the insulin stimulated-to-basal glucose uptake ratio. (**D**) Pyruvate uptake, (**E**) pyruvate oxidation and (**F**) pyruvate release into the medium in the presence or not of 100 nM insulin. (**G**) Glyceroneogenesis assessed by incorporation of pyruvic acid into the glycerol moiety of neutral lipids. (**H**) PCK1 mRNA and protein levels. (**I**) Lipolysis measured by oleic acid release into the medium after stimulation by the β-adrenergic agonist, isoproterenol. (**J**) Gene expression levels of the four *PDK* isoforms. (**K**) PDK4 and Ser293-phosphorylated PDHE1α protein levels. Data represent mean ± SEM expressed as percentage of control (n = 6--12). Open bars: control cells (C), full bars: rosiglitazone-treated cells (R), hatched bars: GW7647-treated cells (GW). \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$: p \< 0.05 for insulin *vs*. unstimulated condition; \$\$\$: p \< 0.001. \#\#: p \< 0.01 for R *vs*. GW; \#\#\#: p \< 0.001.](gr3){#fig3}

![**PDK4 knockdown prevents induction of fatty acid oxidation in brite adipocytes.** Britening-associated changes were explored in 18 day-differentiated hMADS cells transfected with either a control-or PDK4-targeting siRNA and treated or not with rosiglitazone or GW7647 for the last 4 days. (**A**) PDK4 mRNA and protein levels. (**B**) Gene expression levels of *UCP1*, *CIDEA* and *CITED1*. (**C**) Ser293-phosphorylated PDHE1α protein levels. (**D**) Pyruvate release into the medium. (**E**) Glyceroneogenesis assessed by incorporation of pyruvic acid into the glycerol moiety of neutral lipids. (**F**) Pyruvate oxidation. (**G**) Fatty acid (oleate) oxidation. Data represent mean ± SEM expressed as percentage of control (n = 6--11). Open bars: siCtrl-treated cells, full bars: siPDK4-treated cells. \*: p \< 0.05 for R or GW *vs*. C; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$: p \< 0.05 for siPDK4 *vs*. siCtrl; \$\$: p \< 0.01; \$\$\$: p \< 0.001. \#: p \< 0.05 for R *vs*. GW; \#\#\#: p \< 0.001.](gr4){#fig4}

![**PPARα deficiency disrupts WAT britening-induced PDK4 expression *in vivo*.** (**A**, **C**, **E**, **G** and **I**) WT and PPARα-null male mice housed at thermoneutrality were treated with CL316,243 (CL, 0.1 mg/kg/d) or vehicle (DMSO) for 10 days. (**B**, **D**, **F** and **H**) WT and PPARα-null male mice housed at standard temperature were treated with CL316,243 (CL, 1 mg/kg/d) or vehicle (DMSO) for 7 days. Analyses were performed on the inguinal white adipose tissue depot. (**A**, **B**) UCP1 mRNA and protein levels. (**C**--**F**) Gene expression levels of *Cidea*, *Cpt1b*, *Cited1* and *Tmem26*. (**G**, **H**) PDK4 mRNA and protein levels. (**I**) Spearman correlation between UCP1 and PDK4 protein content (n = 23). Data represent mean ± SEM expressed as percentage of vehicle-treated WT mice (n = 7--9 mice per group). Open bars: wild-type mice, hatched bars: PPARα-null mice. NA: not available. \*: p \< 0.05 for CL *vs*. DMSO; \*\*: p \< 0.01; \*\*\*: p \< 0.001. \$: p \< 0.05 for PPARα-null *vs*. wild type; \$\$: p \< 0.01; \$\$\$: p \< 0.001.](gr5){#fig5}

###### 

Significantly enriched biological processes among genes upregulated by rosiglitazone and GW7647.

  Biological processes                                    Upregulated by rosiglitazone   Upregulated by GW7647
  ------------------------------------------------------- ------------------------------ -----------------------
  GO:0006631_Fatty acid metabolic process                 6.76E-08                       2.16E-11
  GO:0006635_Fatty acid beta-oxidation                    6.76E-05                       1.96E-11
  GO:0008610_Lipid biosynthetic process                   7.55E-05                       8.26E-06
  GO:0009062_Fatty acid catabolic process                 2.16E-04                       7.59E-10
  GO:0019395_Fatty acid oxidation                         3.08E-04                       2.00E-09
  GO:0034440_Lipid oxidation                              3.08E-04                       2.00E-09
  GO:0019216_Regulation of lipid metabolic process        9.86E-04                       6.76E-04
  GO:0030258_Lipid modification                           1.14E-03                       3.38E-07
  GO:0044242_Cellular lipid catabolic process             2.07E-03                       1.51E-07
  GO:0016042_Lipid catabolic process                      2.49E-02                       2.66E-04
  GO:0051181_Cofactor transport                           2.51E-02                       1.37E-02
  GO:0006767_Water-soluble vitamin metabolic process      3.07E-02                       3.16E-02
  GO:0050873_Brown fat cell differentiation               3.63E-02                       2.24E-02
  GO:0005996_Monosaccharide metabolic process             3.78E-02                       5.76E-03
  GO:0019318_Hexose metabolic process                     3.83E-02                       3.75E-03
  GO:0010876_Lipid localization                           3.97E-02                       3.38E-02
  GO:0019217_Regulation of fatty acid metabolic process   4.87E-02                       1.80E-02

p Values are adjusted by Benjamini correction.
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